Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial
SP Gampenrieder(Austrian Institute of Technology), Richard Greil(Paracelsus Medical University), Suzana Ilic(Austrian Institute of Technology), Clemens Hufnagl(Austrian Institute of Technology), Hubert Hackl(Innsbruck Medical University), Cornelia Hauser‐Kronberger(Paracelsus Medical University), Andreas Weinhaeusel(Austrian Institute of Technology), Tim Karl(Western Sydney University), Gabriel Rinnerthaler(Medical University of Graz), Marie E. Steiner(Boston University), Walter Pulverer(Austrian Institute of Technology), R. Solano Ángela(Austrian Institute of Technology), E Klinglmayr(Austrian Institute of Technology)
Cited by 0
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery
|New England Journal of Medicine|2015|489
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403